Physician profile
Timothy Edwards
NPI 1356388557
$4,668.66
in general payments reported to CMS, 2019-2025
27 companies · $810 in 2025
The $810 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $29.07 · 2021: $400 · 2022: $876 · 2023: $1,136 · 2024: $1,210 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,086 · Education: $70.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.60 |
| Education | $70.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.28 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $670.04 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $575.25 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Genzyme Corporation | $431.72 | 2022-2025 | |
| Daiichi Sankyo INC. | $292.45 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $263.90 | 2021-2024 | Dificid, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $244.26 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $160.71 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $150.61 | 2022-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $124.93 | 2019-2023 | Linzess |
| Pfizer INC. | $110.38 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $70.95 | 2024-2025 | Vowst |
| Madrigal Pharmaceuticals | $70.26 | 2024 | Rezdiffra, Resmetirom |
| Lumendi LLC | $68.04 | 2025 | |
| Braintree Laboratories, INC. | $65.78 | 2023-2024 | Suflave, Sutab |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $59.97 | 2024 | Zymfentra |
| Phathom Pharmaceuticals, INC. | $45.72 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $34.16 | 2022-2025 | |
| Ucb, INC. | $29.70 | 2024 | Cimzia |
| Amgen INC. | $27.69 | 2022 | |
| Olympus America INC. | $24.71 | 2025 | Endoclot Phs, Single Use Electrosurgical Hemostatic Forceps |
| Nestle Healthcare Nutrition INC. | $18.76 | 2023 | |
| Boston Scientific Corporation | $16.47 | 2024 | Compliance Endokit |
| Qol Medical, LLC | $15.02 | 2019 | |
| Redhill Biopharma INC. | $14.80 | 2021 | |
| Fresenius Kabi USA, LLC | $13.24 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.